Oragenics Inc. (OGEN) Income Statement Analysis - Revenue, Earnings & Profitability Metrics - Stocknear
Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Start Trial

    Oragenics Inc.

    AMEX: OGEN · Real-Time Price · USD
    1.09
    0.03 (2.83%)
    At close: Sep 05, 2025, 3:59 PM
    1.06
    -2.75%
    After-hours: Sep 05, 2025, 07:12 PM EDT

    Oragenics Income Statement

    Financials in USD. Fiscal year is January - December.

    undefined peaked at n/a in undefined and hit its lowest at n/a in undefined. Over the past five years, it has declined by undefined%.

    Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
    Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
    Revenue
    		 n/a 37.65K 131.52K 86.99K
    Cost of Revenue
    		 4.11M 15.49M 44.67K 41.24K
    Gross Profit
    		 -4.11M -27.39K 86.85K 45.75K
    Operating Income
    		 -10.56M -10.67M -14.42M -15.77M
    Interest Income
    		 45.9K 179.8K 135.9K 75.85K
    Pretax Income
    		 -10.57M -20.66M -14.29M -15.71M
    Net Income
    		 -10.57M -20.66M -14.29M -15.71M
    Selling & General & Admin
    		 6.44M 5.45M 4.47M 5.27M
    Research & Development
    		 4.11M 15.49M 10.07M 10.59M
    Other Expenses
    		 -4.11M -10.3M 5K -85.63K
    Operating Expenses
    		 6.44M 10.64M 14.55M 15.77M
    Interest Expense
    		 29.83K 30.59K 15.1K 15.76K
    Selling & Marketing Expenses
    		 n/a n/a n/a n/a
    Cost & Expenses
    		 10.56M 20.94M 14.55M 15.86M
    Income Tax Expense
    		 n/a n/a -127K 16.43K
    Shares Outstanding (Basic)
    		 6.62M 2.25M 2.01M 1.88M
    Shares Outstanding (Diluted)
    		 6.62M 2.25M 2.01M 1.88M
    EPS (Basic)
    		 -1.6 -9.18 -7.11 -8.09
    EPS (Diluted)
    		 -1.6 -9.18 -7.11 -8.09
    EBITDA
    		 -10.56M -20.88M -14.23M -15.65M
    EBIT
    		 -10.6M -20.91M -14.27M -15.7M
    Depreciation & Amortization
    		 38.93K 27.39K 44.67K 41.24K

    Add to Watchlist